Laureen shows you her proprietary “Bubbling and Highlighting Technique”
Download your Free copy of my "Medical Coding From Home Ebook" at the top right corner of this page
Side by side, the 1995 and 1997 Documentation Guidelines and the 2023 CPT® E/M Services Guidelines aren’t so different. Some hospitals and coding and billing entities are under the impression that the new 2023 CPT® evaluation and management (E/M) services guidelines and code changes make things much easier for coding, billing, and auditing processes. It […]
The post Comparing 2023 E/M MDM and Table of Risk appeared first on AAPC Knowledge Center.
I’m trying to get a clear definition of ‘Drug therapy requiring INTENSIVE MONITORING’ to toxicity on the Risk Table.
Google has confused me further.
I’m trying to decipher when it would be in that category verses ‘prescription drug management’ in the moderate.
An example I have that one of my Drs brought up to me is a drug called Noctiva which treats Nocturia.
One of the main side effects is hyponatremia which CAN be life-threatening. So he will need to closely monitor the patients sodium levels.
But my question is what exactly is ‘intensive monitoring for toxicity’. The internet definitely points me to when the patient is in the hospital and getting IV medications of controlled substances and such that might need to be titrated, but does this also apply to clinically monitoring? I think I read that this drug recommends checking sodium levels bi monthly or monthly.
I see that Gentamicin is on a list of requiring intensive monitoring for toxicity. We give this often for UTI’s. So, if the patient has a UTI and we give them this injection (I know I still need 2 out of 3 in MDM), but I can put it in the high spot on the risk table??
Tom Cheezum, O.D., CPC, COPC
The table can be found here: https://docs.google.com/spreadsheets…it?usp=sharing.
An explanatory video is here: https://youtu.be/cCj0yA6AAbA.
Please let me know if you find it helpful.